参考资料: [1]Potent body weight loss, and therapeutic efficacy in a NASH animal model by a novel long-acting GLP-1/GIP/Glucagon tri-agonist (HM15211). EASD 2017. [2]LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery...
However, Aib2-stablized GIP analogs represent strong candidates for fluorophore installation [16, 69], as well as recently reported short (GIP-532) and long (GIP-085) acting GIPR agonists [46], although any compound should be carefully validated using Gipr-Cre reporter and Gipr−/− mice....
Bone marrow responses were studied in (i) mice fed regular or energy-rich diets, (ii) mice treated with hematopoietic stressors including acute 5-fluorouracil (5-FU), pamsaccharide (LPS), and Pam3CysSerLys4 (Pam3CSK4), with or without pharmacological administration of a GIPR agonist, and ...
[1]Potent body weight loss, and therapeutic efficacy in a NASH animal model by a novel long-acting GLP-1/GIP/Glucagon tri-agonist (HM15211). EASD 2017. [2]LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinica...